Contact

Payer

Pharma

Provider

Formulary guidance and transparency from P&T to point of care

Perspectives on Cigna-Express Scripts Deal

Posted by Matt Breese on Mar 13, 2018

Cigna Corp. on March 8 said it would buy Express Scripts Holding Co. in a $67 billion deal, a move that analysts say furthers the trend of payers and PBMs joining together in a single diversified entity. 

Cigna agreed to pay $48.75 in cash and 0.2434 shares of stock of the combined company for each Express Scripts share. Such a move would give the insurer control over the pharmacy space and a greater scale that helps cut costs, according to Jefferies analyst David Windley. 

Read More

Topics: Industry Trends, Branding & Marketing

Trends That Matter for Pharma and Biotech Industry

Posted by Matt Breese on Mar 8, 2018

Today’s pharmaceutical industry requires stakeholders to continually assess the current status and anticipate future changes. PharmExec.com highlights the following trends to watch in 2018 in the pharma and biotech space.

  • Though efforts to repeal the Affordable Care Act failed in 2017, the removal of the individual mandate requirement might reduce by millions the number of Americans with health care coverage and drive up premiums.
Read More

Topics: Industry Trends

Perspectives on Analytics Revolution in the Life Sciences Industry

Posted by Matt Breese on Mar 6, 2018

Looking ahead, life sciences companies should focus on making full use of analytics to translate insights to action, given that the industry is undergoing a transformative shift. 

Over the past few years, life sciences companies have been able to make more sophisticated and precise advances. Yet instead of changing decisions, their insights remain diagnostic. In 2018, leading brands should keep investing in infrastructure and rapid experimentation to generate prescriptive analytics. 

Read More

Topics: Industry Trends, Data & Analytics, Branding & Marketing

Trends That Matter for Immune Globulin

Posted by Matt Breese on Mar 1, 2018

In our weekly Trends That Matter series, we provide infographics, articles and recent news from health care influencers to highlight general trends affecting the pharmaceutical industry. This week's featured topic is Immune Globulin. 

According to our recent payer coverage analysis for immune globulin, combined with news from key health care influencers, market access is shifting in this drug landscape. Pharmacy benefit coverage shows a tremendous increase in restrictive Medicare formularies and a similar shift for health exchange formularies, while standard commercial plans are relaxing coverage.

Read More

Topics: Specialty, Industry Trends

Perspectives on 2018 Pipeline

Posted by Matt Breese on Feb 27, 2018

The rise of CAR-T and other gene therapies, newly identified oncology targets and next-generation sequencing will shape the pipeline for 2018.
 
With the first CAR T-cell therapy approved, this new form of immunotherapy has a bright future. Yet drug companies also need to respond to worrisome side effects, such as severe cytokine release syndrome.
 
Read More

Topics: Specialty, Industry Trends, Product Release

Trends That Matter for Promising Drugs in 2018

Posted by Matt Breese on Feb 22, 2018

FDA’s Center for Drug Evaluation and Research (CDER) approved 46 new drugs in 2017, more than doubling the number of novel medications approved in 2016.

Among the drugs that have been recently launched or will be launched soon, Dupixent, Ocrevus and Imfinizi top the most promising drugs in 2018, according to IgeaHub, a pharmaceutical club for industry influencers. 

Read More

Topics: Industry Trends, Product Release, Branding & Marketing

Perspectives on NASH Market

Posted by Matt Breese on Feb 20, 2018

Non-alcoholic Steatohepatitis (NASH), the severest form of non-alcoholic fatty liver disease (NAFLD), is expected to become the leading cause of liver transplantation by 2020 in the United States. This untapped market might become the next big market in the metabolic disorders segment.  
 
Currently, lifestyle modifications, such as diet and regular exercise, are the main initial therapeutic step. Bariatric surgery is considered the last option, which improves histology and causes massive weight loss. 
 
Read More

Topics: Industry Trends, Market Access, Branding & Marketing

Trends That Matter for HIV

Posted by Matt Breese on Feb 15, 2018

In our weekly Trends that Matter series, we provide infographics, articles and recent news from health care influencers to highlight general trends affecting the pharmaceutical industry. This week's featured topic is HIV. 

According to our recent payer coverage analysis for HIV, combined with news from key health care influencers, market access is shifting in this drug landscape. 

Read More

Topics: Specialty, Industry Trends

Perspectives on OTC Pharma Packaging

Posted by Matt Breese on Feb 13, 2018

As the U.S. reported sales of $45.8 billion for over-the-counter (OTC) medicine in 2016, manufacturing and packaging firms saw great opportunity to capitalize in the space, according to Pharmapack. 
 
To seize the opportunity, OTC makers need to understand the changing market dynamics: growing health care costs, aging populations, demand for more affordable health care and increasing M&A activity.  
 
Read More

Topics: Industry Trends, Market Access, Branding & Marketing

Trends That Matter for Cystic Fibrosis

Posted by Matt Breese on Feb 1, 2018

In our weekly Trends that Matter series, we provide infographics, articles and recent news from health care influencers to highlight general trends affecting the pharmaceutical industry. This week's featured topic is cystic fibrosis. 

According to our recent payer coverage analysis for cystic fibrosis, combined with news from key health care influencers, market access is shifting in this drug landscape. We saw a reduction in both step therapy policies and piror authorizations.

Read More

Topics: Specialty, Industry Trends